Avantor Inc
NYSE:AVTR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 3-Year Average (7.8), the stock would be worth $14.72 (88% upside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.1 | $7.85 |
0%
|
| 3-Year Average | 7.8 | $14.72 |
+88%
|
| 5-Year Average | 8.5 | $16.1 |
+105%
|
| Industry Average | 9.5 | $18.1 |
+131%
|
| Country Average | 6.5 | $12.34 |
+57%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Avantor Inc
NYSE:AVTR
|
5.4B USD | 4.1 | -10.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 599.5 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.3B USD | 11.4 | 25.3 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.5B USD | 9.5 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 32.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
331.7B CNY | 13.3 | 16.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.5B CHF | 10 | -118.3 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.5B USD | 8.9 | 24.4 | |
| US |
|
Waters Corp
NYSE:WAT
|
28.7B USD | 15.5 | 44.6 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD | 7.1 | 19.6 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.2B USD | 11.4 | 29 |
Market Distribution
| Min | 0 |
| 30th Percentile | 4.2 |
| Median | 6.5 |
| 70th Percentile | 10.6 |
| Max | 1 764 211.7 |
Other Multiples
Avantor Inc
Glance View
Avantor Inc. is a unique force in the world of life sciences, a field where precision and reliability are as vital as oxygen to human existence. This Pennsylvania-based corporation manages to weave a complex tapestry of innovation and efficiency in its mission to support scientific advancement across the globe. Avantor operates within a diverse landscape, offering a vast array of products that cater to a wide spectrum of industries, including biotechnology, pharmaceutical, healthcare, industrial, and applied materials. At its core, the company functions as a crucial provider of high-purity materials, customized solutions, and highly specialized services that researchers, scientists, and professionals rely on daily to push the boundaries of what's possible. Avantor makes its money through its strategic integration of manufacturing high-quality laboratory and production materials with a comprehensive distribution network. The company boasts a robust catalog of over six million products, including chemicals, reagents, and other essential laboratory supplies. By leveraging its expansive reach and deep-rooted presence in over 30 countries, Avantor efficiently links product innovation with customer needs. Their operations are not merely transactional but are deeply embedded with a service-oriented approach, ensuring that they not only meet the diverse needs of their clients but also continually innovate to help advance scientific breakthroughs. Profitability stems from both the direct sale of products and long-term service agreements, which foster enduring partnerships and create a strong revenue stream, reinforcing Avantor's stature as a pillar in the life sciences sector.